Showing results (301-310 of 369) with videos related to
Sort By:
Pageof 37
BMJ Oncology|January 31, 2025
Cancer burden across the South Asian Association for Regional Cooperation in 2022Urvish Jain, Faraan Rahim, Bhav Jain, et al.JCO Global Oncology|June 24, 2022
Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional SurveyAvram E Denburg, Adam Fundytus, Muhammad Saghir Khan, et al.Translational Lung Cancer Research|March 4, 2022
Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective studyHuiping Qiang, Yuqiong Lei, Yinchen Shen, et al.Journal of Thoracic Disease|May 20, 2021
High expression of cell adhesion molecule 2 unfavorably impacts survival in non-small cell lung cancer patients with brain metastasesLu Dai, Yi-Hua Li, Ying-Ying Liang, et al.Cancer Immunology, Immunotherapy : CII|April 21, 2020
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohortSabine Schmid, Laetitia A Mauti, Alex Friedlaender, et al.Lung Cancer (Amsterdam, Netherlands)|September 13, 2022
Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II studyAlfredo Addeo, Sacha I Rothschild, Lisa Holer, et al.JCO Precision Oncology|November 22, 2024
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-AnalysisJonathan N Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes, et al.JMIR Research Protocols|October 18, 2023
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled TrialAndré Manuel da Silva Lopes, Sara Colomer-Lahiguera, Célia Darnac, et al.International Immunopharmacology|July 1, 2022
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective studyGiuseppe L Banna, Ornella Cantale, Sethupathi Muthuramalingam, et al.European Radiology|September 8, 2025
Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methodsAlmudena Fuster-Matanzo, Alfonso Picó-Peris, Fuensanta Bellvís-Bataller, et al.Pageof 37